{"entity":{"id":"nct05275374","kind":"trial","name":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation","aka":["ENHANCE"],"tldr":"A phase 1/2 trial of trametinib in colorectal cancer, run by Xynomic Pharmaceuticals, Inc., not yet recruiting.","summary":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation is a phase 1/2, interventional study registered as NCT05275374 by Xynomic Pharmaceuticals, Inc., with a registry enrolment figure of 221 participants, started 2025-12-31 and due to reach its primary completion in 2027-12-30. Interventions recorded: XP-102; Trametinib. Conditions listed: Cancer; BRAF V600 Mutation; Melanoma; Colorectal Cancer; Thyroid Cancer; Nonsmall Cell Lung Cancer. Primary outcome: Characterize the safety of XP-102.; Evaluate the pharmacokinetics of XP-102.; Establish maximum tolerated dose of XP-102.. Colorectal eligibility wording from the registry: \"* Advanced malignant solid tumor patients with a BRAF V600 mutation (limited to melanoma, colorectal cancer, non-small cell lung cancer, or thyroid cancer)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05275374","url":"https://clinicaltrials.gov/study/NCT05275374"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","braf-v600e-colorectal"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["trametinib"],"companies":["xynomic-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05275374","phase":"1/2","setting":"A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)","sponsor":"Xynomic Pharmaceuticals, Inc.","enrolled":221,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05275374/","neighbours":{"cancer":[{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/"},{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/"}],"company":[{"id":"xynomic-pharmaceuticals","kind":"company","name":"Xynomic Pharmaceuticals","route":"/companies/xynomic-pharmaceuticals/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}